These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 14697898)

  • 21. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties.
    Chan HH; Tse MK; Kumar S; Zhuo L
    Eur J Pharmacol; 2018 Jan; 818():254-262. PubMed ID: 29050969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
    Seif-El-Nasr M; Atia AS; Abdelsalam RM
    Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
    Lai CT; Yu PH
    Toxicol Appl Pharmacol; 1997 Jan; 142(1):186-91. PubMed ID: 9007048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
    Steyn SJ; Castagnoli K; Steyn S; Castagnoli N
    Exp Neurol; 2001 Apr; 168(2):434-6. PubMed ID: 11259132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
    Miklya I
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (-)Deprenyl-N-oxide, a (-)deprenyl metabolite, is cytoprotective after hypoxic injury in PC12 cells, or after transient brain ischemia in gerbils.
    Szilágyi G; Simon L; Wappler E; Magyar K; Nagy Z
    J Neurol Sci; 2009 Aug; 283(1-2):182-6. PubMed ID: 19332347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.
    Mytilineou C; Leonardi EK; Radcliffe P; Heinonen EH; Han SK; Werner P; Cohen G; Olanow CW
    J Pharmacol Exp Ther; 1998 Feb; 284(2):700-6. PubMed ID: 9454817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxygen-glucose deprivation-induced changes in organotypic cultures of the rat hippocampus.
    Bali B; Nagy Z; Kovács KJ
    Ideggyogy Sz; 2007 Mar; 60(3-4):140-3. PubMed ID: 17451055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptotic and antiapoptotic effect of (-)deprenyl and (-)-desmethyl-deprenyl on human cell lines.
    Szende B; Magyar K; Szegedi Z
    Neurobiology (Bp); 2000; 8(3-4):249-55. PubMed ID: 11225516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J
    J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.